How Medicare cuts could limit heart transplant evaluations

Australia's healthcare system rests on a simple promise: every patient, regardless of postcode or income, should be able to access the specialists they need. Yet the way the Medicare Benefits Schedule funds cardiology services is under growing pressure, and the downstream effects may reshape who gets assessed for a heart transplant at all. Bulk-billing incentives, scheduled fee reviews, and tightening federal budgets are converging at a moment when demand for advanced cardiac care is climbing.

Heart transplantation remains one of the most resource-intensive interventions in modern medicine. A complete evaluation involves cardiologists, transplant surgeons, nurses, social workers, psychologists, pharmacists, and radiologists working in sequence over weeks or months. Each consultation, each imaging study, and each multidisciplinary meeting is supported by a complex web of rebates and inpatient funding arrangements. When the rebate side of that equation is trimmed, the entire pathway is exposed.

The current moment calls for a closer look at what happens to transplant evaluation lists when the funding that supports them is pared back. Australian examples from Sydney, Melbourne, Brisbane, and smaller regional centres show that the consequences are already arriving in subtle forms, and they will sharpen if MBS reductions proceed without a clear plan to protect advanced cardiac services.

The Medicare Benefits Schedule and advanced cardiac care

The Medicare Benefits Schedule sets the rebate Australian patients receive for specialist consultations, imaging, and procedural work. For cardiology, the schedule covers everything from a routine echocardiogram in a suburban Brisbane clinic to a complex right heart catheterisation at a major tertiary centre. Every few years, the Department of Health commissions a review of specific MBS items, and fee adjustments follow.

When a review panel recommends a reduction in the rebate for a complex cardiology service, the impact is rarely confined to that single line item. Specialist rooms that bulk bill absorb the cut directly. Rooms that charge above the rebate can find that their patient base narrows, because out-of-pocket costs rise. For low-income patients referred for advanced care, even a modest gap can become a deciding factor in whether they return for follow-up testing.

Cardiology service	Typical patient journey under current MBS	Patient journey after a fee reduction
Initial specialist consultation	Rebate covers most of the fee; gap is modest	Gap widens; some patients delay or skip
Echocardiogram and stress testing	Standard investigation, often bulk billed	Practices limit bulk billing to pensioners and concession card holders
Right heart catheterisation	Performed at public hospitals with no out-of-pocket cost	Public waiting lists lengthen as private providers scale back
Multidisciplinary transplant evaluation meeting	Funded through inpatient arrangements and Medicare-supported consultations	Hospitals absorb higher costs; some reduce the number of formal meetings

The table illustrates how a single MBS adjustment can ripple through an entire evaluation pathway. None of the rows on the right describe a catastrophic collapse, but together they describe a slow squeeze that patients feel appointment by appointment.

How fee reductions reshape transplant evaluation lists

Heart transplant evaluation is not a single appointment. It typically begins with a referral from a general cardiologist to a transplant centre, often based at St Vincent's Hospital in Sydney, the Alfred in Melbourne, the Royal Prince Alfred, or the Prince Charles Hospital in Brisbane. The first visit is followed by a battery of tests: blood work, imaging, cardiopulmonary exercise testing, cardiac MRI, and sometimes a coronary angiogram. A multidisciplinary team then meets to discuss suitability.

Each step depends on access to specialist time, advanced imaging, and coordinated scheduling. The Medicare rebate does not pay for the multidisciplinary meeting itself, but it underwrites many of the consultations and investigations that feed into it. When those rebates fall, hospitals face a difficult choice. They can absorb the loss from existing budgets, which means less money for other services. They can pass the cost on to patients in the form of larger gaps, which discourages follow-through. Or they can reduce the volume of evaluations they accept, which is the most direct route to a shorter list.

In practice, the choice is rarely clean. Public hospitals often absorb the loss first, then quietly tighten criteria. A patient with a complex history of diabetes and kidney disease, who would previously have been given the benefit of a full evaluation, may now be considered unsuitable before testing begins. That is not a deliberate policy decision. It is a consequence of constrained resourcing meeting a growing caseload, and it is a pattern that has been observed in several Australian jurisdictions as MBS items have been trimmed over the past decade.

The Australian patient experience

For patients in regional and outer metropolitan areas, the experience is already uneven. A person in Cairns or Darwin referred for transplant evaluation is likely to travel to Brisbane, Sydney, or Melbourne for the assessment. Travel costs, time away from work, and the logistics of repeated visits are real barriers, even before any fee changes are considered.

Medicare cuts amplify those barriers. A patient who would previously have bulk-billed their way through pre-transplant testing may suddenly face a gap of several hundred dollars for a single cardiac MRI. The Heart Foundation Australia has consistently highlighted out-of-pocket costs as a driver of treatment dropout, particularly for people on lower incomes. When the gap appears in the evaluation phase, before a patient is even listed, the risk is that suitable candidates never reach the waiting list at all.

Culturally, Australian medicine prides itself on the principle of universal access. The phrase "fair go" gets used often in policy debates, and it carries weight in healthcare too. Patients in Adelaide and Perth have a reasonable expectation that the same transplant evaluation pathway available in Sydney will be available to them, even if it means travelling interstate. Funding decisions that quietly thin out that pathway undermine a quietly held national assumption, and the people who feel the loss first are usually those with the fewest alternatives.

Workforce and administrative pressure inside cardiology units

The clinical workforce that delivers transplant evaluation is small and highly trained. Cardiac transplantation in Australia is concentrated in a handful of units, each relying on a limited pool of cardiologists, surgeons, perfusionists, and specialist nurses. When MBS rebates fall, the financial pressure on these units grows, but the supply of trained staff does not increase to compensate.

Heart transplant coordinators, who shepherd patients through the evaluation process, are often funded through a mix of hospital budgets, state health department grants, and Medicare-supported consultations. A reduction in consultation rebates can translate into a smaller administrative team, slower communication with referring doctors, and longer waits for the first transplant clinic appointment. In Adelaide, where the state government has invested heavily in the new Royal Adelaide Hospital, the cardiac unit still depends on a fragile balance of funding sources that MBS changes can disrupt.

There is also a less visible effect. Senior cardiologists who supervise transplant evaluations are frequently involved in research, teaching, and the training of advanced trainees. When hospital revenue from specialist consultations falls, support for these roles can be quietly reduced. The long-term consequence is a thinning of the expertise pipeline at exactly the moment Australia's population is ageing and heart failure is becoming more common across the country.

What can be done to protect the transplant evaluation pathway

Protecting access to transplant evaluation requires attention to several levers at once. Clinicians, patient advocates, and policy makers have raised the following measures in submissions to recent MBS reviews and parliamentary inquiries.

• Submissions to MBS reviews should include detailed cost data from transplant units, not just aggregate cardiology figures, so that review panels understand the downstream impact of fee changes.
• Hospitals should publish waiting times for transplant evaluation clinics, giving patients and referrers a clearer picture of access and creating a benchmark for policy makers.
• The Heart Foundation Australia and the Cardiac Society of Australia and New Zealand should coordinate joint statements when MBS changes affect transplant-related items, speaking with one voice rather than several.
• Federal and state governments should consider ring-fenced funding for transplant coordination roles, recognising that the multidisciplinary team is a clinical service in its own right.
• Patients asked to pay larger gaps during evaluation should be able to access clear information about financial assistance, including the PBS Safety Net, state-based travel schemes, and hospital social work services.
• Regional referral pathways should be strengthened, so that patients in places like Townsville, Hobart, or regional Western Australia are not lost to follow-up between referral and first specialist appointment.
• Private health insurers should be encouraged to cover pre-transplant evaluation as part of their cardiology packages, reducing reliance on Medicare rebates for the assessment phase.

Each of these steps addresses a different part of the pathway. None of them replaces the underlying need for stable Medicare funding, but together they reduce the chance that a single fee cut will be the reason a suitable candidate never reaches the transplant list.

Australian patients and clinicians have long taken the existence of a transplant evaluation pathway for granted. The infrastructure exists, the expertise is world class, and the willingness to share stories and advocate is strong. The current moment calls for that advocacy to be aimed at the funding decisions that determine whether the pathway stays open, narrows, or closes altogether. If you or someone you know has been affected by changes in access to advanced cardiac care, add your voice to the campaign and share that experience, because every story strengthens the case for protecting this vital service.